Eligibility

Eligible Ages

Between 60 Years and 100 Years

Eligible Sex

All

Accepts Healthy Volunteers

No

Criteria

Inclusion:

- Age ≥ 60 years;

- Biochemical diagnosis of hypercalcemic (corrected serum calcium >10.2 mg/dL or
ionized serum calcium >1.31 mmol/dL or 5.2 mg/dL on at least one serum sample)
primary hyperparathyroidism as determined by board-certified endocrinologist or
endocrine surgeon;

- Undergoing parathyroidectomy at UF Health;

- Willing and able to give informed consent.

Exclusion:

- Failure to provide informed consent;

- Biochemical diagnosis of eucalcemic primary hyperparathyroidism (corrected serum
calcium ≤10.2 mg/dL or ionized serum calcium ≤1.31 mmol/dL or 5.2 mg/dL on at least
one serum sample);

- Elected not to undergo parathyroidectomy at UF Health;

- Major surgery as deemed by principal investigator or hip/knee replacement in the
past 6 months;

- Fractures to the hands, arms or legs within the last 6 months;

- Traumatic accident (i.e. motor vehicle collision, fall from elevation, etc.)
resulting in orthopedic trauma or requiring prolonged immobilization (>2 weeks)
within the last 6 months;

- Blood transfusion within the past 3 months;

- Self-reported myocardial infarction, cerebrovascular accident, or unstable angina
within the past 6 months;

- NYHA Class 3 or 4 congestive heart failure;

- Major psychiatric disorder;

- Cancer requiring treatment in the past 1 year (including metastatic cancer), except
for locally treated non-melanoma skin cancers or cancers that have clearly been
cured or in the opinion of the investigator carry an excellent prognosis (e.g.,
Stage 1 cervical cancer);

- Renal failure requiring hemodialysis or peritoneal dialysis

- Use of bone-modifying therapies (alendronate [Fosamax], zoledronic acid [Reclast],
denosumab [Prolia or Xgeva], or romosozumab [Evenity]) within 1 month of planned
surgery

- Planning to permanently leave the area within 3 months of parathyroidectomy;

- Vision or hearing impairment - defined as unable to read or listen/follow
instructions despite the use of maximal assistive devices (i.e. contact lenses,
glasses, hearing aids, etc.)

- Participating in another clinical trial or has received an investigational product
within 30 days prior to screening/enrollment.